RLS
MCID: RST001
MIFTS: 51

Restless Legs Syndrome (RLS)

Categories: Mental diseases, Neuronal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Restless Legs Syndrome

MalaCards integrated aliases for Restless Legs Syndrome:

Name: Restless Legs Syndrome 11 19 42 52 75 53 43 14 63 16 71 33
Restless Leg Syndrome 19 42
Willis-Ekbom Disease 11 42
Ekbom Syndrome 42 33
Wed 11 42
Restless Legs Syndrome, Susceptibility to 38
Wittmaack-Ekbom Syndrome 11
Willis Ekbom Disease 19
Ekbom's Syndrome 42
Restless Legs 41
Rls 42

Classifications:



External Ids:

Disease Ontology 11 DOID:0050425
ICD9CM 34 333.94
MeSH 43 D012148
NCIt 49 C84501
SNOMED-CT 68 32914008
ICD11 33 1254916765
UMLS 71 C0035258

Summaries for Restless Legs Syndrome

MedlinePlus Genetics: 42 Restless legs syndrome is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, often described as crawling, pulling, or itching, deep within both legs. The feelings usually occur while the affected person is sitting or lying down and are worse at night. Movement, such as kicking, stretching, rubbing, or pacing, make the discomfort go away, at least temporarily. The unpleasant feelings and the resulting need to move the legs often make it difficult for an affected person to fall asleep or stay asleep.The signs and symptoms of restless legs syndrome range from mild to severe; people with mild cases may experience symptoms a few times a month, while those with more severe cases may have symptoms every night. In severe cases, the uncomfortable feelings can affect the arms or other parts of the body in addition to the legs.Many people with restless legs syndrome also experience uncontrollable, repetitive leg movements that occur while they are sleeping or while relaxed or drowsy. When these movements occur during sleep, they are called periodic limb movements of sleep (PLMS); when they occur while a person is awake, they are called periodic limb movements of wakefulness (PLMW). It is unclear whether PLMS and PLMW are features of restless legs syndrome itself or represent similar, but separate, conditions.Restless legs syndrome and PLMS can affect the quality and amount of sleep. As a result of these conditions, affected individuals may have difficulty concentrating during the day, and some develop mood swings, depression, or other health problems.Researchers have described early-onset and late-onset forms of restless legs syndrome. The early-onset form begins before age 45, and sometimes as early as childhood. The signs and symptoms of this form usually worsen slowly with time. The late-onset form begins after age 45, and its signs and symptoms tend to worsen more rapidly.

MalaCards based summary: Restless Legs Syndrome, also known as restless leg syndrome, is related to restless legs syndrome 7 and restless legs syndrome 6, and has symptoms including tremor, back pain and headache. An important gene associated with Restless Legs Syndrome is RLS4 (Restless Legs Syndrome 4), and among its related pathways/superpathways are Alpha-synuclein signaling and Methylphenidate Pathway, Pharmacodynamics. The drugs Benzocaine and Tannic acid have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and spinal cord.

MedlinePlus: 41 Restless legs syndrome (RLS) causes a powerful urge to move your legs. Your legs become uncomfortable when you are lying down or sitting. Some people describe it as a creeping, crawling, tingling, or burning sensation. Moving makes your legs feel better, but not for long. RLS can make it hard to fall asleep and stay asleep. In most cases, there is no known cause for RLS. In other cases, RLS is caused by a disease or condition, such as anemia or pregnancy. Some medicines can also cause temporary RLS. Caffeine, tobacco, and alcohol may make symptoms worse. Lifestyle changes, such as regular sleep habits, relaxation techniques, and moderate exercise during the day can help. If those don't work, medicines may reduce the symptoms of RLS. Most people with RLS also have a condition called periodic limb movement disorder (PLMD). PLMD is a condition in which a person's legs twitch or jerk uncontrollably, usually during sleep. PLMD and RLS can also affect the arms. NIH: National Heart, Lung, and Blood Institute

GARD: 19 Restless legs syndrome (RLS) is a neurological condition that causes an irresistible urge to move the legs. The movement is triggered by strange or uncomfortable feelings, which occur mostly while the affected person is sitting or lying down and are worse at night. Movement (i.e. kicking, stretching, rubbing, or pacing) makes the discomfort go away, at least temporarily. Many people with Restless legs syndrome also have uncontrollable, repetitive leg movements that occur while they are sleeping or while relaxed or drowsy. RLS likely results from a combination of genetic and environmental factors, many of which are unknown. The syndrome may also be classified in several types (RLS1, RLS2, RLS3, RLS4, RLS5, RLS6, RLS7) according to the location in specific chromosomes of some of the genes that are associated with an increased risk (susceptibility) to have the syndrome.

PubMed Health : 63 Restless legs syndrome: Restless legs syndrome (RLS) is a disorder that causes a strong urge to move your legs. This urge to move often occurs with strange and unpleasant feelings in your legs. Moving your legs relieves the urge and the unpleasant feelings. People who have RLS describe the unpleasant feelings as creeping, crawling, pulling, itching, tingling, burning, aching, or electric shocks. Sometimes, these feelings also occur in the arms. The urge to move and unpleasant feelings happen when you're resting and inactive. Thus, they tend to be worse in the evening and at night.

NINDS: 52 Restless legs syndrome (RLS) is characterized by unpleasant sensations in the legs and an irresistible urge to move them. Individuals affected with the disorder often describe the sensations as throbbing, pulling, or creeping. The sensations range in severity from uncomfortable to irritating to painful. Symptoms commonly occur in late afternoon or evening and are most severe at night, when the person is resting. Moving the legs or walking typically relieves the discomfort but the symptoms often recur. RLS is both a sleep and a neurological sensory disorder.

Disease Ontology: 11 A central nervous system disease characterized by throbbing, pulling creeping or other unpleasant sensations in the legs and the irresistible urge to move them.

Wikipedia: 75 Restless legs syndrome (RLS), also known as Willis-Ekbom disease (WED), is generally a long-term... more...

Related Diseases for Restless Legs Syndrome

Diseases in the Restless Legs Syndrome family:

Restless Legs Syndrome 1 Restless Legs Syndrome 2
Restless Legs Syndrome 3 Restless Legs Syndrome 4
Restless Legs Syndrome 6 Restless Legs Syndrome 5
Restless Legs Syndrome 7 Restless Legs Syndrome 8

Diseases related to Restless Legs Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 537)
# Related Disease Score Top Affiliating Genes
1 restless legs syndrome 7 33.4 RLS7 MEIS1
2 restless legs syndrome 6 33.4 RLS6 BTBD9
3 periodic limb movement disorder 32.6 SLC6A3 SKOR1 HCRT DRD2 BTBD9
4 sleep disorder 32.4 SLC6A3 MAOB HCRT
5 movement disease 32.3 SLC6A3 MAOB DRD3 DRD2
6 attention deficit-hyperactivity disorder 31.9 SLC6A3 PTPRD MAOB HCRT DRD3 DRD2
7 migraine with or without aura 1 31.8 SLC6A3 MAOB HCRT DRD3 DRD2
8 anxiety 31.5 SLC6A3 MAOB HCRT DRD3 DRD2
9 parkinsonism 31.5 SLC6A3 MAOB DRD3 DRD2
10 rem sleep behavior disorder 31.5 SLC6A3 MAOB HCRT
11 major depressive disorder 31.4 SLC6A3 MAOB HCRT DRD3 DRD2
12 essential tremor 31.4 SLC6A3 SKOR1 DRD3
13 mood disorder 31.4 SLC6A3 MAOB HCRT DRD3 DRD2
14 pathological gambling 31.3 SLC6A3 MAOB DRD3 DRD2
15 impulse control disorder 31.3 SLC6A3 MAOB DRD3 DRD2
16 bruxism 31.3 HCRT DRD3 DRD2
17 multiple system atrophy 1 31.3 SLC6A3 MAOB DRD2
18 eating disorder 31.2 SLC6A3 HCRT DRD2
19 gilles de la tourette syndrome 31.2 SLC6A3 DRD3 DRD2 BTBD9
20 psychotic disorder 31.1 TFRC SLC6A3 MAOB DRD3 DRD2
21 supranuclear palsy, progressive, 1 31.1 SLC6A3 MAOB HCRT DRD2
22 tic disorder 31.0 SLC6A3 DRD3 DRD2 BTBD9
23 personality disorder 31.0 SLC6A3 MAOB DRD3 DRD2
24 obsessive-compulsive disorder 31.0 SLC6A3 PTPRD MAOB DRD3 DRD2
25 dystonia 30.9 SLC6A3 MAOB HCRT DRD3 DRD2
26 tobacco addiction 30.9 SLC6A3 DRD3 DRD2
27 withdrawal disorder 30.9 SLC6A3 HCRT DRD2
28 dementia, lewy body 30.9 SLC6A3 MAOB HCRT
29 substance abuse 30.8 SLC6A3 HCRT DRD3 DRD2
30 dysthymic disorder 30.7 SLC6A3 HCRT
31 oppositional defiant disorder 30.7 SLC6A3 DRD3 DRD2
32 kleptomania 30.6 SLC6A3 DRD2
33 huntington disease 30.6 SLC6A3 MAOB HCRT DRD2
34 alcohol use disorder 30.6 SLC6A3 DRD3 DRD2
35 opiate dependence 30.6 SLC6A3 HCRT DRD3 DRD2
36 post-traumatic stress disorder 30.6 SLC6A3 MAOB HCRT DRD2
37 drug dependence 30.6 SLC6A3 DRD3 DRD2
38 delusional disorder 30.6 SLC6A3 DRD2
39 restless legs syndrome 2 11.8
40 restless legs syndrome 1 11.8
41 restless legs syndrome 3 11.7
42 restless legs syndrome 4 11.7
43 restless legs syndrome 5 11.7
44 restless legs syndrome 8 11.7
45 iron metabolism disease 11.2
46 l-ferritin deficiency 11.2
47 parkinson disease, late-onset 11.0
48 end stage renal disease 10.9
49 neuropathy 10.9
50 polyneuropathy 10.8

Graphical network of the top 20 diseases related to Restless Legs Syndrome:



Diseases related to Restless Legs Syndrome

Symptoms & Phenotypes for Restless Legs Syndrome

UMLS symptoms related to Restless Legs Syndrome:


tremor; back pain; headache; syncope; excessive daytime somnolence; pain; chronic pain; sciatica; snoring; sleep disturbances; seizures; vertigo/dizziness; sleeplessness

Drugs & Therapeutics for Restless Legs Syndrome

PubMed Health treatment related to Restless Legs Syndrome: 63

Restless legs syndrome (RLS) has no cure. If a condition or medicine triggers RLS, it may go away or get better if the trigger is relieved or stopped. RLS can be treated. The goals of treatment are to: Prevent or relieve symptoms Increase the amount of sleep you're getting and improve the quality of your sleep Treat or correct any underlying condition that may trigger or worsen RLS Mild cases of RLS often are treated with lifestyle changes and sometimes with periodic use of medicines. More severe RLS usually is treated with daily medicines.

Drugs for Restless Legs Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 147)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
2
Tannic acid Approved Phase 4 1401-55-4 16129878 16129778
3
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
4
Suvorexant Approved, Investigational Phase 4 1030377-33-3 57505028 24965990
5
Promethazine Approved, Investigational Phase 4 60-87-7 4927
6
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
7
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
8
Prednisolone Approved, Vet_approved Phase 4 50-24-8 4894 5755
9
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5 1875
10
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 4159 6741
11
Levetiracetam Approved Phase 4 102767-28-2 441341 5284583
12
Topiramate Approved Phase 4 97240-79-4 5284627
13
Amitriptyline Approved Phase 4 50-48-6 2160
14
Valproic acid Approved, Investigational Phase 4 99-66-1 3121
15
Rizatriptan Approved Phase 4 145202-66-0, 144034-80-0 5078
16
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
17
Memantine Approved, Investigational Phase 4 41100-52-1, 19982-08-2 4054
18
Duloxetine Approved Phase 4 136434-34-9, 116539-59-4 60835
19
Donepezil Approved Phase 4 120014-06-4 3152
20
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
21
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
22
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 60857
23
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
24
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
25
Propranolol Approved, Investigational Phase 4 318-98-9, 525-66-6 62882 4946
26
Apomorphine Approved, Investigational Phase 4 41372-20-7, 58-00-4 6005
27
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
28
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7 4897
29 Hypoglycemic Agents Phase 4
30 Hypnotics and Sedatives Phase 4
31 Orexin Receptor Antagonists Phase 4
32
Methylprednisolone Acetate Phase 4 584547
33 Iron Supplement Phase 4
34 Omega 3 Fatty Acid Phase 4
35 Gastrointestinal Agents Phase 4
36 Emetics Phase 4
37 Neurotransmitter Agents Phase 4
38 Dopamine agonists Phase 4
39 Dopamine Agents Phase 4
40 Antiparkinson Agents Phase 4
41 Antioxidants Phase 4
42 Protective Agents Phase 4
43 Excitatory Amino Acid Antagonists Phase 4
44 Cardiotonic Agents Phase 4
45 Sympathomimetics Phase 4
46
Benserazide Approved, Investigational Phase 3 322-35-0 2327
47
Levodopa Approved Phase 3 59-92-7, 63-84-3 6047
48
Cabergoline Approved Phase 3 81409-90-7 54746
49
Lisuride Approved, Investigational Phase 3 18016-80-3 28864
50
Bupropion Approved Phase 2, Phase 3 31677-93-7, 34841-39-9, 34911-55-2 444

Interventional clinical trials:

(show top 50) (show all 203)
# Name Status NCT ID Phase Drugs
1 Effects of Gabapentin Enacarbil on Intensity of Cortical Arousal, Heart Rate, Blood Pressure and Anterior Tibialis EMG Responses Associated With PLMs During Sleep in Patients With RLS Using a Novel Computer Assisted Scoring System Unknown status NCT02424695 Phase 4 Gabapentin Enacarbil (GEn);Placebo
2 A 12-Week, Multi-Center, Double-Blind, Placebo-Controlled, Parallel Group, Flexible Dose Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome (RLS) in RLS Patients With Sleep Disturbance and Periodic Limb Movements (PLM) During Sleep Completed NCT00373542 Phase 4 ropinirole CR-RLS
3 Autonomic Function and Cardiovascular Risk in Restless Legs Syndrome: AUTOREST, a Case-control Study and a Randomized, Double-blind, Placebo-controlled, Parallel-group, 4-week, Multicenter Study of 0.25mg Pramipexole vs. Placebo in Patients With RLS Completed NCT02025608 Phase 4 Pramipexole;Placebo
4 A Phase IV Randomised, Double-blind, Active and Placebo-controlled, 6-week Trial to Investigate the Efficacy and Safety of a Starting (and Fixed) Dose 0.25 mg Pramipexole (Mirapex®) in Patients With Idiopathic Restless Legs Syndrome Completed NCT00375284 Phase 4 Pramipexole
5 Post-marketing Clinical Study of Gabapentin Enacarbil -Non-blinded Study in Restless Legs Syndrome (RLS) Patients With Moderate Renal Impairment- Completed NCT01981941 Phase 4 Gabapentin enacarbil
6 Gabapentin Enacarbil Post-marketing Clinical Study A Randomized, Double-blind, Placebo-controlled, Parallel-group Study in Subjects With Restless Legs Syndrome. Completed NCT03053427 Phase 4 Placebo;Gabapentin enacarbil
7 A Method to Switch From Oral Dopamine Agonists to Rotigotine in Patients With Restless Legs Syndrome Completed NCT01976871 Phase 4 Rotigotine
8 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol, Mirapexin) 0.125-0.75 mg/Day Per os to Investigate the Long-term Efficacy, Safety and Tolerability in Patients With Idiopathic Moderate to Severe Restless Legs Syndrome for 26 Weeks Followed by a 26 Week Open-label Extension Treatment Period Completed NCT00472199 Phase 4 Pramipexole;Placebo
9 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With 0.125-0.75 mg/Day Pramipexole (Sifrol®, Mirapexin®) Orally for 12 Weeks to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome Associated With Mood Disturbances Completed NCT00356096 Phase 4 pramipexole
10 A Phase IV Randomised, Double-blind, Placebo-controlled, Dose Titration Trial With Pramipexole (Sifrol®, Mirapexin®) 0.125-0.75 mg/Day Per os for 12 Weeks to Investigate the Effects on RLS Symptoms (IRLS) and Sleep Disturbance (MOS Sleep Scale) in Out-patients With Idiopathic Restless Legs Syndrome Completed NCT00349531 Phase 4 Pramipexole
11 A Parallel Group Study to Evaluate the Efficacy and Safety of Ropinirole for 26 Weeks and to Further Evaluate the Incidence of Augmentation and Rebound for a Further 40 Weeks Open-label Extension Treatment Period in Subjects Suffering From Moderate to Severe Restless Legs Syndrome. Completed NCT00329602 Phase 4 Placebo;Ropinirole
12 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Effacy and Safety of Topiramate in Subjects With Restless Legs Syndrome (RLS) Completed NCT00200941 Phase 4 Topiramate
13 Exploratory Study of the Efficacy, Practicability and Safety of Intravenous Iron Supplementation Therapy in Moderate to Severe Restless Legs Syndrome With Iron Deficiency or Anaemia in the 3rd Trimester of Pregnancy Completed NCT01245777 Phase 4 ferric carboxymaltose
14 Multicenter, Double-Blind, Placebo-Controlled, Two-Arm, Randomized, Parallel, Treatment Intervention, Sleep Lab Phase 4 Study to Assess the Effect of Rotigotine on Nocturnal Blood Pressure in Patients With Idiopathic Restless Legs Syndrome Completed NCT01455012 Phase 4 Rotigotine;Placebo
15 Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome : a Pilot Randomized, Placebo-controlled Study Completed NCT01823770 Phase 4 Rotigotine;Placebo patchs
16 Randomized, Double-Blind, Placebo-Controlled, Fixed-Dose, Parallel-Group Study to Compare the Efficacy, Tolerability, and Safety of 3 Doses of Gabapentin Enacarbil (GSK1838262) With Placebo in Treatment of Moderate-to-Severe Primary RLS Completed NCT01668667 Phase 4 GSK1838262 600 mg;GSK1838262 450 mg;GSK1838262 300 mg;GSK1838262 Placebo match
17 An Open-Label Prospective Study of Restless Legs Patients Switched to Ropinirole From Pramipexole to Help Determine the Equipotent Dose Completed NCT00344994 Phase 4 pramipexole
18 A Multicenter Open-Label Extension Study to Evaluate the Efficacy and Safety of HORIZANT (Gabapentin Enacarbil) Extended-Release Tablets in Adolescents Aged 13 to 17 Years Old With Moderate-to-Severe Primary Restless Legs Syndrome Recruiting NCT02633683 Phase 4 HORIZANT 600 mg
19 Open Label Assessment of Pitolisant (Wakix) as Adjunct Therapy for Patients With Refractory Restless Legs Syndrome Recruiting NCT05581576 Phase 4 Pitolisant
20 Nighttime Agitation and Restless Legs Syndrome in People With Alzheimer's Disease Recruiting NCT03082755 Phase 4 Gabapentin Enacarbil;Placebo Oral Tablet
21 Efficacy of Suvorexant in Patients With Effectively Treated Restless Legs Syndrome and Persistent Chronic Insomnia: A Randomized Placebo-Controlled Crossover Trial Recruiting NCT04706091 Phase 4 Suvorexant
22 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
23 Optimum Frequency and Timing of Oral Iron Administration for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder Enrolling by invitation NCT04610827 Phase 4 Ferrous sulfate
24 Open Label and Placebo-Controlled Assessment of Sublingual Apomorphine (Kynmobi) as Adjunct Therapy for Patients With Refractory Restless Legs Syndrome Not yet recruiting NCT05529095 Phase 4 Apomorphine Sublingual Film;Placebo
25 Treating Leg Symptoms in Women With X-linked Adrenoleukodystrophy: A Key to Improving Sleep and Gait Performance Not yet recruiting NCT05003648 Phase 4 Pramipexole;Placebo
26 A Randomized Controlled Trial of Pramipexole for Restless Leg Syndrome in Peritoneal Dialysis Patients Terminated NCT03817554 Phase 4 Pramipexole
27 Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome Terminated NCT02117076 Phase 4 Gabapentin immediate release;Gabapentin enacarbil extended release
28 Butrans for Treatment of Restless Legs Syndrome Withdrawn NCT02138357 Phase 4 buprenorphine transdermal delivery system (BTDS);Placebo for BTDS patch
29 Pregabalin (Lyrica) for the Treatment of Restless Legs Syndrome Withdrawn NCT00584246 Phase 4 Pregabalin (Lyrica);Placebo
30 Evaluation of Cholecalciferol Supplementation in Chronic Kidney Disease Patients With Restless Leg Syndrome Withdrawn NCT03063190 Phase 4 Vitamin D;Placebo Oral Tablet
31 Vitamin D in the Treatment of Primary Restless Legs Syndrome: 12 Weeks, Triple-blinded, Randomized, Placebo-controlled Trial Unknown status NCT02256215 Phase 2, Phase 3 Vitamin D
32 Swiss Restless Legs Syndrome Trial (SRLS) A Double-blind, Randomised, Crossover Trial Investigating the Efficacy and Safety of the Dopamine Agonist Pramipexole (Sifrol®, 0.25-0.75 mg Per Day) Versus Levodopa / Benserazide (Madopar® DR, 125-375 mg Per Day) in Patients With Restless Legs Syndrome Completed NCT00144209 Phase 3 pramipexole;levodopa in combination with benserazide
33 Study RXP110908, a Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in the Treatment of Restless Legs Syndrome (RLS) and Associated Sleep Disturbance Completed NCT00748098 Phase 3 GSK1838262 Extended Release Tablets;Placebo
34 A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole in Patients Suffering From Restless Legs Syndrome (RLS) Completed NCT00363857 Phase 3 Ropinirole
35 A Multicenter 3:1-randomized Placebo-controlled Double-blind Phase IIIb Study on the Effects of Ropinirole on Mood/(Subclinical) Depression in the Therapy of Patients With Moderate to Severe Idiopathic RLS in Germany Completed NCT00357097 Phase 3 Ropinirole
36 A 12-Week, Randomized, Double-Blind, Parallel Group, Multicentre Study to Assess the Tolerability and Clinical Benefits of Ropinirole Extended Release (XR) Tablets Compared With Ropinirole Immediate Release (IR) Tablets in Subjects With Restless Legs Syndrome (RLS) Completed NCT00314860 Phase 3 ropinirole Extended Release (XR)
37 A 4-Week, Randomized, Double-Blind, Cohort Study to Evaluate the Safety and Tolerability of Converting From Ropinirole Immediate Release (IR) to Ropinirole Controlled Release for RLS (CR-RLS) Formulation (Formerly Ropinirole Extended Release [XR]) in Patients With Restless Legs Syndrome (RLS) Completed NCT00256854 Phase 3 Ropinirole IR 1 mg;Ropinirole IR 2 mg;Ropinirole IR 1 mg Placebo;Ropinirole IR 2 mg Placebo;Ropinirole CR 2 mg;Ropinirole CR 3 mg;Ropinirole CR 2 mg Placebo;Ropinirole CR 3 mg Placebo
38 Randomized, Double Blind, 12-Month Study Of Pregabalin In Subjects With Restless Legs Syndrome Completed NCT00806026 Phase 3 placebo and pregabalin;pramipexol;Pregabalin
39 An Open-label Extension Trial to Investigate the Safety and Tolerability of Long-term Treatment With Transdermal Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00498108 Phase 3 Rotigotine
40 Sequential Compression Devices for Treatment of Restless Legs Syndrome - a Prospective, Randomized, Sham-Controlled Study Completed NCT00479531 Phase 3
41 A Randomised, Double-blind Study to Evaluate the Efficacy and Safety of Pramipexole at Fixed Doses of 0.25 mg, 0.5 mg, and 0.75 mg in Patients With Idiopathic Restless Legs Syndrome for 6 Weeks, Followed by a 46-week Open-label Long-term Study Completed NCT00390689 Phase 3 Pramipexole 0.125 mg tablet;Pramipexole 0.5 mg tablet
42 DIalysis Symptom COntrol-Restless Legs Syndrome Trial (DISCO-RLS Trial): A Randomized Controlled Trial Completed NCT03806530 Phase 3 Gabapentin;Ropinirole;Placebo Gabapentin;Placebo Ropinirole
43 A Randomized, Double-blind, Placebo Controlled Dose Titration Trial With 0.125-0.75 mg Pramipexole (Sifrol®) Orally q.n. to Investigate the Safety and Efficacy in Out-patients With Idiopathic Restless Legs Syndrome for 6 Weeks Completed NCT00654498 Phase 3 Pramipexole;Placebo
44 Long-term Study - Long-term Efficacy and Safety of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients Completed NCT02658188 Phase 3 ASP8825
45 A Double-blind, Placebo-controlled, Randomised Withdrawal Study of 3 Month Duration in Patients Suffering From Idiopathic Restless Legs Syndrome Who Responded to a Preceding, 6-month Treatment With Open-label Pramipexole Including Titration (0.125, 0.25, 0.5, 0.75 mg Orally q.n.) Completed NCT00152958 Phase 3 Pramipexole
46 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial to Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Legs Syndrome Completed NCT00135993 Phase 3 Rotigotine
47 A Randomized, Double-blind, Placebo-controlled, Parallel Group Clinical Trial Comparing Fixed Doses of 0.25 mg, 0.50 mg and 0.75 mg Pramipexole (Mirapex®) Administered Orally to Investigate the Safety and Efficacy in Patients With Idiopathic Restless Legs Syndrome for 12 Weeks Completed NCT00133198 Phase 3 Pramipexole
48 Efficacy of Vitamin C, Vitamin E and Their Combination for Treatment of Restless Legs Syndrome in Hemodialysis Patients: a Randomized Double-blind, Placebo-controlled Trial Completed NCT01125033 Phase 2, Phase 3 Vitamin C & Vitamin E;Vitamin C;Vitamin E;Vitamin C Placebo & Vitamin E Placebo
49 A Double-blind, Randomized, Placebo-controlled Multicenter Efficacy Study for the Treatment of Patients With Restless Legs Syndrome (RLS) Completed NCT00627003 Phase 3 Cabergoline
50 A Randomized, Double-Blind, Placebo-Controlled, 3-Way Crossover, Multicenter Polysomnography Study Of Pregabalin And Pramipexole In Adults With Restless Legs Syndrome Completed NCT00991276 Phase 3 pregabalin;placebo;pramipexole

Search NIH Clinical Center for Restless Legs Syndrome

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carbamazepine
Clonazepam

Cochrane evidence based reviews: restless legs syndrome

Genetic Tests for Restless Legs Syndrome

Anatomical Context for Restless Legs Syndrome

Organs/tissues related to Restless Legs Syndrome:

MalaCards : Heart, Lung, Spinal Cord, Cingulate Cortex, Kidney, Brain, Cortex

Publications for Restless Legs Syndrome

Articles related to Restless Legs Syndrome:

(show top 50) (show all 5432)
# Title Authors PMID Year
1
Uncovering the mechanism of Radix Paeoniae Alba in the treatment of restless legs syndrome based on network pharmacology and molecular docking. 62 41
36401463 2022
2
Explainable Machine-Learning-Based Characterization of Abnormal Cortical Activities for Working Memory of Restless Legs Syndrome Patients. 62 41
36298144 2022
3
Association Of Bone Mineral Profile With Restless Leg Syndrome In Patients With End Stage Renal Disease. 62 41
36414586 2022
4
Circadian variation of hypocretin-1 (orexin A) in restless legs syndrome. 53 62
19013101 2009
5
Circadian rhythm of CSF monoamines and hypocretin-1 in restless legs syndrome and Parkinson's disease. 53 62
18207455 2009
6
Spinocerebellar ataxia type 1, 2, and 3 and restless legs syndrome: striatal dopamine D2 receptor status investigated by [11C]raclopride positron emission tomography. 53 62
16941469 2006
7
Support for dopaminergic hypoactivity in restless legs syndrome: a PET study on D2-receptor binding. 53 62
16816393 2006
8
Ferritin levels in the cerebrospinal fluid and restless legs syndrome: effects of different clinical phenotypes. 53 62
16268375 2005
9
CSF iron, ferritin and transferrin levels in restless legs syndrome. 53 62
15743333 2005
10
Decreased transferrin receptor expression by neuromelanin cells in restless legs syndrome. 53 62
15136682 2004
11
Iron metabolism and the risk of restless legs syndrome in an elderly general population--the MEMO-Study. 53 62
12242538 2002
12
Increased CSF hypocretin-1 (orexin-A) in restless legs syndrome. 53 62
12196669 2002
13
Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. 53 62
10762522 2000
14
Selective serotonin receptor uptake inhibitors can reduce restless legs symptoms. 53 62
10724062 2000
15
Sex modulates the outcome of subthalamic nucleus deep brain stimulation in patients with Parkinson's disease. 62
36204861 2023
16
Clinical efficacy and safety of intravenous ferric carboxymaltose treatment for restless legs symptoms and low serum ferritin in children with autism spectrum disorder. 62
36265207 2022
17
Prevalence of obstructive sleep apnea as assessed by polysomnography in psychiatric patients with sleep-related problems. 62
35029795 2022
18
Prospective evaluation of sleep disturbances in chronic pancreatitis and its impact on quality of life: a pilot study. 62
34981297 2022
19
Can calcitonin gene-related peptide monoclonal antibody improve migraine and restless legs syndrome? 62
36306631 2022
20
The incidence, complications, and treatment of iron deficiency in pregnancy. 62
36153674 2022
21
Restless legs syndrome in patients with psoriasis: association with inflammation and sleep quality. 62
36468846 2022
22
Association between clinical outcomes and restless legs syndrome in Japanese patients with ulcerative colitis. 62
35852410 2022
23
Restless legs syndrome and cognitive function among adults: a systematic review and meta-analysis. 62
36472687 2022
24
Neuroanatomy and Functional Connectivity in Patients with Parkinson's Disease with or without Restless Legs Syndrome. 62
35999489 2022
25
Usefulness of electronic stimulation in restless legs syndrome: a pilot study. 62
33487095 2022
26
Does physical activity timing differentially correlate with symptoms of restless legs syndrome in adults with multiple sclerosis? 62
36049405 2022
27
Possible association between vitamin B12 deficiency and restless legs syndrome. 62
36401952 2022
28
Effects of aromatherapy massage on the severity of restless legs syndrome in hemodialysis patients: A randomized clinical trial. 62
35060333 2022
29
Prevalence of sleep disorders in a large French cohort of aircrew members and risk of in-flight sleepiness. 62
36087520 2022
30
Intravenous iron therapy in the pediatric sleep clinic: a single institution experience. 62
35912699 2022
31
Cognitive strategies to improve symptoms of restless legs syndrome. 62
36447357 2022
32
Noninvasive Vagus Nerve Stimulation: A New Therapeutic Approach for Pharmacoresistant Restless Legs Syndrome. 62
36400697 2022
33
Vitamin D deficiency and restless legs syndrome during pregnancy: walking in sunshine? 62
36377836 2022
34
Polysomnographic features of idiopathic restless legs syndrome: a systematic review and meta-analysis of 13 sleep parameters and 23 leg movement parameters. 62
35903949 2022
35
Further Studies on the Role of BTBD9 in the Cerebellum, Sleep-like Behaviors and the Restless Legs Syndrome. 62
36244636 2022
36
Restless legs syndrome due to brainstem stroke: A systematic review. 62
36063288 2022
37
The prevalence and associated factors of seasonal exacerbation of subjective symptoms in Japanese patients with restless legs syndrome. 62
36442422 2022
38
Pagophagia and restless legs syndrome are highly associated with iron deficiency and should be included in histories evaluating anemia. 62
36322094 2022
39
Restless Legs Syndrome and the Eyes: Spectral-Domain Optic Coherence Tomography Study. 62
35238834 2022
40
The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factors. 62
36324033 2022
41
Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease. 62
36342675 2022
42
More than sleepiness: prevalence and relevance of nonclassical symptoms of obstructive sleep apnea. 62
36101923 2022
43
Prevalence of sleep disorders in children with chronic kidney disease: a meta-analysis. 62
35445975 2022
44
Study Protocol: Sleep Effects on Poststroke Rehabilitation Study. 62
35948301 2022
45
Sleep microstructure and clinical characteristics of patients with restless legs syndrome. 62
35924664 2022
46
Presynaptic adenosine receptor heteromers as key modulators of glutamatergic and dopaminergic neurotransmission in the striatum. 62
36375695 2022
47
Sleep and Stroke: Opening Our Eyes to Current Knowledge of a Key Relationship. 62
36190654 2022
48
A longitudinal study of restless legs symptoms among patients with depression. 62
35191781 2022
49
Primary dysmenorrhoea in adolescents and young women: A twin family study of maternal transmission, genetic influence and associations. 62
35754341 2022
50
Longitudinal Studies of Sleep Disturbances in Parkinson's Disease. 62
36018498 2022

Variations for Restless Legs Syndrome

Expression for Restless Legs Syndrome

Search GEO for disease gene expression data for Restless Legs Syndrome.

Pathways for Restless Legs Syndrome

Pathways related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.37 SLC6A3 MAOB
2
Show member pathways
10.29 SLC6A3 MAOB DRD3 DRD2

GO Terms for Restless Legs Syndrome

Cellular components related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dopaminergic synapse GO:0098691 9.26 SLC6A3 DRD2
2 obsolete integral component of presynaptic membrane GO:0099056 8.8 SLC6A3 PTPRD DRD2

Biological processes related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 modulation of chemical synaptic transmission GO:0050804 10 PTPRD DRD2 BTBD9
2 behavioral response to cocaine GO:0048148 9.92 DRD3 DRD2
3 positive regulation of renal sodium excretion GO:0035815 9.91 DRD3 DRD2
4 response to ethanol GO:0045471 9.91 SLC6A3 MAOB DRD3 DRD2
5 G protein-coupled receptor internalization GO:0002031 9.89 DRD3 DRD2
6 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.88 DRD3 DRD2
7 response to cocaine GO:0042220 9.88 SLC6A3 DRD3 DRD2
8 negative regulation of cytosolic calcium ion concentration GO:0051481 9.87 DRD2 DRD3
9 dopamine catabolic process GO:0042420 9.86 SLC6A3 MAOB
10 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.85 DRD3 DRD2
11 adenohypophysis development GO:0021984 9.84 SLC6A3 DRD2
12 hyaloid vascular plexus regression GO:1990384 9.83 SLC6A3 DRD2
13 dopamine uptake involved in synaptic transmission GO:0051583 9.81 SLC6A3 DRD2
14 adenylate cyclase-inhibiting dopamine receptor signaling pathway GO:0007195 9.8 DRD2 DRD3
15 regulation of potassium ion transport GO:0043266 9.78 DRD2 DRD3
16 synaptic transmission, dopaminergic GO:0001963 9.77 DRD3 DRD2
17 regulation of dopamine uptake involved in synaptic transmission GO:0051584 9.76 DRD2 DRD3
18 locomotory behavior GO:0007626 9.76 SLC6A3 MEIS1 DRD3 DRD2
19 response to histamine GO:0034776 9.67 DRD2 DRD3
20 acid secretion GO:0046717 9.62 DRD2 DRD3
21 regulation of biological quality GO:0065008 9.58 DRD3 DRD2
22 regulation of locomotion involved in locomotory behavior GO:0090325 9.56 DRD3 DRD2
23 response to iron ion GO:0010039 9.43 TFRC SLC6A3 DRD2
24 prepulse inhibition GO:0060134 9.1 SLC6A3 DRD3 DRD2

Molecular functions related to Restless Legs Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 heterocyclic compound binding GO:1901363 9.56 SLC6A3 DRD2
2 dopamine binding GO:0035240 9.46 SLC6A3 DRD2
3 dopamine neurotransmitter receptor activity GO:0004952 8.96 DRD3 DRD2
4 dopamine neurotransmitter receptor activity, coupled via Gi/Go GO:0001591 8.92 DRD3 DRD2

Sources for Restless Legs Syndrome

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....